New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
09:06 EDTNUVA, STJ, DGX, ABCO, FLDM, CMN, THOR, ELGX, BSXPiper Jaffray's technical analyst holds an analyst/industry conference call
Technical Analyst Johnson provides a technical review of the firm's Medical Technology covered universe ahead of 4Q results on an Analyst/Industry conference call to be held on January 10 at 10 am.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2015
15:02 EDTSTJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 60c... Boeing (BA), consensus $1.42... Abbott Laboratories (ABT), consensus 50c... Thermo Fisher Scientific (TMO), consensus $1.78... EMC (EMC), consensus 41c... Illinois Tool Works (ITW), consensus $1.28... St. Jude Medical (STJ), consensus $1.00... Northern Trust (NTRS), consensus 96c... Check Point Software (CHKP), consensus 95c... Polaris Industries (PII), consensus $1.58... Interpublic Group (IPG), consensus 27c... New York Community Bancorp (NYCB), consensus 26c... B/E Aerospace (BEAV), consensus 76c... Owens Corning (OC), consensus 54c... Knight Transportation (KNX), consensus 37c.
14:52 EDTTHORThoratec could possibly get $65-$70 per share in takeover, says Northland
Subscribe for More Information
13:56 EDTSTJ, THORSt. Jude Medical bid for Thoratec makes strategic sense, says JPMorgan
Subscribe for More Information
12:40 EDTSTJ, THORSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTTHOR, STJThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
12:29 EDTSTJ, THORSt. Jude Medical in talks to acquire Thoratec, Bloomberg reports
Subscribe for More Information
12:21 EDTSTJ, THOROn The Fly: Top stock stories at midday
Subscribe for More Information
10:20 EDTTHOR, STJCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:14 EDTTHORHigh option volume stocks:
Subscribe for More Information
10:12 EDTTHORThoratec calls active on sharp rally
Thoratec August 55 and 65 calls are active on 260 contracts (50 puts). August call option implied volatility is at 55, September is at 50; compared to its 52-week range of 24 to 51. Active calls suggests traders taking positions for price movement.
09:58 EDTTHORThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
07:22 EDTBSXBoston Scientific should be bought on pullbacks, says RBC Capital
RBC Capital expects Boston Scientific to report slightly higher than expected Q2 EPS and in-line revenue. The firm expects the company's results to be boosted by strength in ICDs and OUS DES stents. RBC is confident that the company's EPS can grow by low teen percentage levels over the long-term and recommends buying the shares on pullbacks.
July 20, 2015
09:08 EDTBSXBoston Scientific begins study of resorbable drug-eluting scaffold system
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study, or FAST, is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.
08:32 EDTSTJSt. Jude Medical receives FDA approval for MR-conditional 5-column paddle lead
Subscribe for More Information
07:32 EDTDGXAlzheimer's Association to hold a conference
Subscribe for More Information
July 16, 2015
10:00 EDTABCOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:34 EDTSTJSt. Jude Medical receives FDA approval for spinal cord stimulation trial system
St. Jude Medical (STJ) announced it received FDA approval of the Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple (AAPL) technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation, or SCS, trial experience. "Patients undergoing SCS trials consistently tell us about challenges they find in navigating the SCS trial system, from programming the device, to discomfort from the programming cables, to management of both issues. These hindrances may impede the integration of the technology into their daily activities, which shifts their focus away from evaluating the effectiveness of SCS therapy,” said pain specialist Dr. Jason E. Pope, president of Summit Pain Alliance in Santa Rosa, California. “By providing a discreet trial system, St. Jude Medical will help patients focus more on their potential pain relief and functional improvements, and less about the burdens common to traditional trial systems.”
07:35 EDTABCOThe Advisory Board initiated with a Buy at Canaccord
Target $66.
July 15, 2015
10:59 EDTTHORHeartWare drops after analyst cuts target to $60
Shares of HeartWare are moving lower after Northland analyst Suraj Kalia cut his price target for the name to $60 from $70. The company manufactures implantable heart pumps for patients suffering from advanced heart failure. Recent sheep data for the company's MVAD Pump with new impeller design show a "flowrate profile that seems to be on a downtrend over time," Kalia told investors this morning in a research note. The incomplete data raise more questions, the analyst contends. The MVAD Pump is a continuous axial flow pump, one-third the size of HeartWare's current heart pump, HVAD, according to the company. Kalia believes the MVAD will be more "problematic in patient management" than the HVAD over the long term. The analyst has an Underperform rating on HeartWare, Northland's sell rating equivalent. Shares of medical device company are down $2.22 to $71.22 in morning trading. Its peer Thoratec (THOR) is up 16c to $46.69.
08:57 EDTTHORLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use